KYKaifeng Yang

Kaifeng Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kaifeng Yang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A score based on MRI imaging variables can predict time to moderate progression in mild cognitive impairment: Multimodal data integration study

    by Elzbieta Jodlowska-Siewert, Limeng Liu, Kaifeng Yang, Denis Ostroushko, Pamela L. Lutsey, Thierry Chekouo, Sandra E. Safo, For The Alzheimer'S Disease Neuroimaging Initiative

    Background: Mild cognitive impairment (MCI) is an intermediate stage between normal aging and Alzheimer's disease (AD). Because there is no treatment for AD, it is vital to establish which patients are at a higher risk of disease progression, and might benefit from early intervention. Objective: This study investigates whether a score based on clusters of MRI and lipidomic variables can predict the time to moderate progression in MCI. Methods: We analyzed MRI and lipidomics data from 480 individuals with MCI (mean age 72.14 years, range 55–90 years). Moderate progression was defined as a ≥ 2.5-point increase in the Clinical Dementia Rating Scale Sum of Boxes (baseline mean CDR-SB of 1.2, range 0–10 points). Multi-source data integration and clustering methods were used to derive predictive scores. Results: The MRI-based score outperformed the lipidomics score (c-index: 0.754 versus 0.666). A 1-unit increase in the MRI score was linked to a 13% higher risk of moderate progression. Individuals in the top 25% of MRI scores had a 3-fold greater risk of decline. Conclusions: An MRI-based score offers a simple, effective tool to predict moderate MCI progression and identify high-risk individuals for AD.

  • Open Access

    Supervised Integrative Biclustering with applications to Alzheimer's Disease

    by Kaifeng Yang, Thierry Chekouo, Sandra E. Safo

    Multiple types or views of data (e.g. genetics, proteomics) measured on the same set of individuals are now popularly generated in many biomedical studies. A particular interest might be the detection of sample subgroups (e.g. subtypes of disease) characterized by specific groups of variables. Biclustering methods are well-suited for this problem since they can group samples and variables simultaneously. However, most existing biclustering methods cannot guarantee that the detected sample clusters are clinically meaningful and related to a clinical outcome because they independently identify biclusters and associate sample clusters with a clinical outcome. Additionally, these methods have been developed for continuous data when integrating data from different views and do not allow for a mixture of data distributions. We propose a new formulation of biclustering and prediction method for multi-view data from different distributions that enhances our ability to identify clinically meaningful biclusters by incorporating a clinical outcome. Sample clusters are defined based on an adaptively chosen subset of variables and their association with a clinical outcome. We use extensive simulations to showcase the effectiveness of our proposed method in comparison to existing methods. Real-world applications using lipidomics, imaging, and cognitive data on Alzheimer's disease(AD) identified biclusters with significant cognitive differences that other methods missed. The distinct lipid categories and brain regions characterizing the biclusters suggest potential new insights into pathology of AD.

  • Open Access

    Impact of Underlying Chronic Medical Conditions on COVID-19 Outcomes Among People Living with HIV: A Retrospective Analysis from the Minnesota Fairview Network

    by Taiwo Opeyemi Aremu, Kaifeng Yang, Han Lu, Oluwatosin Esther Oluwole, Kehinde Oluwatosin Adeyinka

    (1) Background: The Coronavirus Disease 2019 (COVID-19) pandemic has raised concerns about the impact of underlying medical conditions on the health outcomes of people living with HIV (PLWH). This study aimed to assess how pre-existing chronic medical conditions affect the health outcomes of PLWH infected with COVID-19. (2) Methods: A retrospective study using data from the Minnesota Fairview network (1 January 2020–31 December 2022) was conducted. Fisher’s exact test, the Kruskal–Wallis rank-sum test, and ordinal logistic regressions with a Benjamini–Hochberg (BH) adjustment on p-values were used to assess the influence of chronic conditions on COVID-19 severity, adjusting for age and gender. (3) Results: Among 216 records, significant associations were found for a stroke, chronic kidney disease, lung disease, and neurologic conditions (p < 0.05). Type 1 diabetes was marginally significant (0.05 < p < 0.1). After adjusting for age and sex, a stroke (p = 0.0008, BH-adjusted p = 0.0044) and chronic kidney disease (p = 0.0003, BH-adjusted p = 0.0033) significantly increased the risk of severe COVID-19 outcomes. (4) Conclusions: Pre-existing medical conditions should be considered in the clinical management and public health interventions for PLWH infected with COVID-19. Tailored strategies are essential to mitigate the higher risk of severe outcomes in PLWH with specific chronic comorbidities.

  • Open Access

    Impact of Underlying Chronic Medical Conditions on COVID-19 Outcomes among People Living with HIV: A Retrospective Analysis from the Minnesota Fairview Network

    by Taiwo Opeyemi Aremu, Kaifeng Yang, Han Lu, Oluwatosin Esther Oluwole, Kehinde Oluwatosin Adeyinka

    (1) Background: The COVID-19 pandemic has raised concerns about the impact of underlying medical conditions on the health outcomes of people living with HIV (PLWH). This study aimed to assess how pre-existing chronic medical conditions affect the health outcomes of PLWH infected with COVID-19. (2) Methods: A retrospective study using data from the Minnesota Fairview network (January 1, 2020 - December 31, 2022) was conducted. Fisher’s Exact Test, Kruskal-Wallis rank sum test, and ordinal logistic regressions with Benjamini-Hochberg (BH) adjustment on p-values were used to assess the influence of chronic conditions on COVID-19 severity, adjusting for age and gender. (3) Results: Among 216 records, significant associations were found for stroke, chronic kidney disease, lung disease, and neurologic conditions (p<0.05). Type 1 diabetes was marginally significant (0.05<p<0.1). After adjusting for age and sex, stroke (p=0.0008, BH-adjusted p=0.0044) and chronic kidney disease (p=0.0003, BH-adjusted p=0.0033) significantly increased the risk of severe COVID-19 outcomes. (4) Conclusions: Pre-existing medical conditions should be considered in the clinical management and public health interventions for PLWH with COVID-19. Tailored strategies are essential to mitigate the higher risk of severe outcomes in PLWH with specific chronic comorbidities.

  • Open Access

    Developing A Baseline Metabolomic Signature Associated with COVID-19 Severity: Insights from Prospective Trials Encompassing 13 U.S. Centers

    by Kaifeng Yang, Zhiyu Kang, Weihua Guan, Sahar Lotfi-Emran, Zachary J. Mayer, Candace R. Guerrero, Brian T. Steffen, Michael A. Puskarich, Christopher J. Tignanelli, Elizabeth Lusczek, et al.

    Metabolic disease is a significant risk factor for severe COVID-19 infection, but the contributing pathways are not yet fully elucidated. Using data from two randomized controlled trials across 13 U.S. academic centers, our goal was to characterize metabolic features that predict severe COVID-19 and define a novel baseline metabolomic signature. Individuals (n = 133) were dichotomized as having mild or moderate/severe COVID-19 disease based on the WHO ordinal scale. Blood samples were analyzed using the Biocrates platform, providing 630 targeted metabolites for analysis. Resampling techniques and machine learning models were used to determine metabolomic features associated with severe disease. Ingenuity Pathway Analysis (IPA) was used for functional enrichment analysis. To aid in clinical decision making, we created baseline metabolomics signatures of low-correlated molecules. Multivariable logistic regression models were fit to associate these signatures with severe disease on training data. A three-metabolite signature, lysophosphatidylcholine a C17:0, dihydroceramide (d18:0/24:1), and triacylglyceride (20:4_36:4), resulted in the best discrimination performance with an average test AUROC of 0.978 and F1 score of 0.942. Pathways related to amino acids were significantly enriched from the IPA analyses, and the mitogen-activated protein kinase kinase 5 (MAP2K5) was differentially activated between groups. In conclusion, metabolites related to lipid metabolism efficiently discriminated between mild vs. moderate/severe disease. SDMA and GABA demonstrated the potential to discriminate between these two groups as well. The mitogen-activated protein kinase kinase 5 (MAP2K5) regulator is differentially activated between groups, suggesting further investigation as a potential therapeutic pathway.